Trial Profile
Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizumab (Avastin) in Combination With Escalating Doses of Oral AZD2171 for Patients With Advanced Malignancies.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cediranib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 15 Jan 2014 Status changed from active, no longer recruiting to discontinued; according to M.D. Anderson Cancer Center record.
- 15 Jan 2014 Status changed from active, no longer recruiting to discontinued; according to M.D. Anderson Cancer Center record.
- 23 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.